drugset / Trial / NCT06559436
Extending the Time Window for Intravenous Tenecteplase in Patients With Distal Medium Vessel Occlusions Stroke
Recruiting
560 enrolled
The First Affiliated Hospital of University of Science and Technology of China
RandomizedParallel-groupSingle-blindTreatment
Summary
To assess the safety and efficacy of beyond time window TNK intravenous thrombolysis for distal Medium Vessel Occlusion (MeVO) related stroke in a prospective randomized clinical trial.
Timeline
- Start
- 2024-10-02
- Primary completion
- 2026-09-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenecteplase | Protein / enzyme biologic | 0.25 mg/kg | Intravenous |